Breast cancer immunohistochemistry can be useful in triage of some HNPCC families
- PMID: 19123071
- DOI: 10.1007/s10689-008-9226-4
Breast cancer immunohistochemistry can be useful in triage of some HNPCC families
Abstract
Immunohistochemistry of tumour samples is increasingly used in the triage of families where hereditary non-polyposis colorectal cancer (HNPCC) due to mismatch repair defects is suspected. Usually, this is undertaken in tumours that are a recognised part of the spectrum of HNPCC-related cancers e.g. colon or endometrial cancers. Although breast cancers are not classed as part of this spectrum, this study examined the extent to which some breast tumours do arise by the mismatch repair pathway in these families. This may have clinical utility in families where an individual with a 'classic HNPPC-related' tumour is not available for evaluation. Immunohistochemistry of a breast tumour may identify an individual in whom germline mutation testing is worthwhile.
Similar articles
-
Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.Fam Cancer. 2007;6(3):301-10. doi: 10.1007/s10689-007-9124-1. Epub 2007 Apr 24. Fam Cancer. 2007. PMID: 17453358
-
[The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].Orv Hetil. 2005 May 15;146(20):1009-16. Orv Hetil. 2005. PMID: 15945244 Hungarian.
-
Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis.Dis Colon Rectum. 1999 Jun;42(6):710-5; discussion 715-6. doi: 10.1007/BF02236922. Dis Colon Rectum. 1999. PMID: 10378593
-
Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.Evid Rep Technol Assess (Full Rep). 2007 May;(150):1-180. Evid Rep Technol Assess (Full Rep). 2007. PMID: 17764220 Free PMC article. Review.
-
Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.Dis Markers. 2004;20(4-5):207-13. doi: 10.1155/2004/391039. Dis Markers. 2004. PMID: 15528786 Free PMC article. Review.
Cited by
-
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.Cell Oncol (Dordr). 2014 Feb;37(1):1-8. doi: 10.1007/s13402-013-0158-0. Epub 2013 Dec 4. Cell Oncol (Dordr). 2014. PMID: 24306927 Review.
-
Is the controversy on breast cancer as part of the Lynch-related tumor spectrum still open?Fam Cancer. 2012 Dec;11(4):681-3. doi: 10.1007/s10689-012-9562-2. Fam Cancer. 2012. PMID: 22890886
-
Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families.BMC Cancer. 2010 Oct 11;10:544. doi: 10.1186/1471-2407-10-544. BMC Cancer. 2010. PMID: 20937110 Free PMC article.
-
Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.Mod Pathol. 2013 Jul;26(7):944-54. doi: 10.1038/modpathol.2012.232. Epub 2013 Feb 1. Mod Pathol. 2013. PMID: 23370770 Free PMC article.
-
Does breast carcinoma belong to the Lynch syndrome tumor spectrum? - Somatic mutational profiles vs. ovarian and colorectal carcinomas.Oncotarget. 2020 Apr 7;11(14):1244-1256. doi: 10.18632/oncotarget.27538. eCollection 2020 Apr 7. Oncotarget. 2020. PMID: 32292574 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical